![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Enhertu (trastuzumab deruxtecan) is a HER2-directed antibody-drug conjugate which is being evaluated in phase 2 clinical trials for the treatment of patients with Gastroesophageal Cancer.
Lead Product(s): Trastuzumab Deruxtecan
Therapeutic Area: Oncology Product Name: Enhertu
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2024
Details:
First patient has been screened in a new phase III clinical trial that uses Signatera, as a companion diagnostic to identify muscle-invasive urothelial carcinoma patients eligible for investigational treatment with Genentech’s cancer immunotherapy drug Tecentriq.
Lead Product(s): Atezolizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2021
Details:
The collaboration is focused on a investigator-initiated multi-center, Phase II randomized clinical trial of Ribociclib (Kisqali®), a CDK4/6 inhibitor, for the treatment of ER-positive breast cancer (LEADER).
Lead Product(s): Ribociclib,Hormone therapy
Therapeutic Area: Oncology Product Name: Kisqali
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Massachusetts General Hospital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 27, 2020